Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12623000604606
ACTRN12623000604606
Recruiting
Phase 4

Randomized head-to-head trial of proton pump inhibitor (PPI) vs topical corticosteroids (TCs) post food bolus impaction and/or for untreated patients with Eosinophilic esophagitis (EoE).

orthern Adelaide Local Health Network0 sites72 target enrollmentJune 2, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsEosinophilic oesophagitis (EoE)Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Eosinophilic oesophagitis (EoE)
Sponsor
orthern Adelaide Local Health Network
Enrollment
72
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 2, 2023
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
orthern Adelaide Local Health Network

Eligibility Criteria

Inclusion Criteria

  • •Patients who present with a food bolus obstruction (FBO) or dysphagia.
  • •Diagnosed with EoE, which is defined as eosophageal biopsy containing \>15 eosinophils per high power field, in any one oesophageal location (peak count).
  • •On nil current treatment, or willing to cease treatment with PPI or diet for 8 weeks prior to repeat endoscopy.

Exclusion Criteria

  • •Exclusion criteria will comprise any of the following conditions or factors:
  • •Coexistent medical conditions that could cause oesophageal eosinophilia (e.g. primary hypereosinophilic syndrome, organ transplant recipient, connective tissue disorder, Crohn’s disease)
  • •Medications that could cause oesophageal eosinophilia (e.g. antiepileptic, clozapine)
  • •Medications that could suppress the immune system and decrease eosinophil count (e.g,systemic corticosteroids, immunosuppressant such as methotrexate or azathioprine, biological agents such as anti – TNF)
  • •Usual residence is a forensic facility
  • •Intellectual disability

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
A randomized study of the influence of proton pump inhibitors on antiplatelet effect by Clopidogrel based on CYP2C19 genotypesAngina pectoris and myocardial infarction
JPRN-UMIN000003898ational Cerebral and Cardiovascular Center150
Active, not recruiting
Not Applicable
A clinical trial to investigate if proton beam therapy with chemotherapy given before surgery for patients with oesophageal cancer that has spread to the surrounding tissues, significantly reduces the severe side effects to the heart and lungs and allows immunotherapy to be started sooner after surgery when compared with standard radiotherapy and chemotherapy before surgery, and whether this delivers value to the NHS and patientsOesophageal cancerCancer
ISRCTN50098578niversity College London170
Recruiting
Not Applicable
A multi-institutional clinical trial of proton beam therapy for localized intermediate-risk prostate cancerlocalized intermediate-risk prostate cancer
JPRN-UMIN000025453niversity of Tsukuba200
Active, not recruiting
Not Applicable
Phase II clinical study on efficacy of proton pump inhibitors pre-treatment in osteosarcoma patients undergoing chemiotherapy - Proton pump inhibitors in osteosarcoma patientsOsteosarcomaMedDRA version: 9.1Level: LLTClassification code 10031293Term: Osteosarcoma localised
EUCTR2006-005179-17-ITISTITUTI ORTOPEDICI RIZZOLI
Recruiting
Phase 3
on-randomized controlled study comparing proton beam therapy and hepatectomy for resectable hepatocellular carcinoma(JCOG1315C, SPRING study)resectable hepatocellular carcinoma
JPRN-UMIN000027811Japan Clinical Oncology Group (JCOG)290